Functional genomics identifies therapeutic targets for MYC-driven cancer
Masafumi Toyoshima(Nippon Medical School Hospital), Carla Grandori(Precision for Medicine (United States)), Heather L. Howie(Bloodworks Northwest), Maki Imakura, James Annis(Rosetta Stone (United States)), Andrey Loboda(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter S. Linsley(Rosetta Stone (United States)), Jason P. Frazier(Rosetta Stone (United States)), Aaron N. Chang(Baylor University Medical Center), B. Nelson Chau(Unknown), Julie R. Park(Seattle Children's Hospital), Michele A. Cleary(The Kids Research Institute Australia), Ryan Walsh(Texas Neurology)
Cited by 252
Related Papers
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
CTLA-4 is a second receptor for the B cell activation antigen B7.
|The Journal of Experimental Medicine|1991|1.7k
The Myc/Max/Mad Network and the Transcriptional Control of Cell Behavior
|Annual Review of Cell and Developmental Biology|2000|1.3k
Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
|Cancer Discovery|2017|964